Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5600 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PDEδ/NAMPT IN-1
CAS:<p>PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) with a dissociation constant (KD) of 0.410 nM and nicotinamide phosphoribosyltransferase (NAMPT) with an inhibitory concentration (IC50) of 2.21 nM. It disrupts KRAS-related signaling by inhibiting NAMPT's role in the synthesis of nicotinamide adenine dinucleotide (NAD+), consequently inducing apoptosis in pancreatic cancer cells with KRAS mutations. This compound holds potential for research in KRAS-mutant pancreatic cancer.</p>Fórmula:C26H30N4O4SCor e Forma:SolidPeso molecular:494.61GPD-1116
CAS:<p>GPD-1116 is an orally active inhibitor of phosphodiesterase (PDE)4 and PDE1. The compound effectively reduces smoke-induced apoptosis in lung cells. Additionally, GPD-1116 has shown efficacy in various animal disease models, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma, and pulmonary arterial hypertension.</p>Fórmula:C22H16N4OCor e Forma:SolidPeso molecular:352.39CP-31398
CAS:<p>CP-31398 stabilizes the active conformation of p53 in cancer cells with either mutated or wild-type p53, enhancing its activity. Additionally, CP-31398 upregulates target genes of p53 such as p21WAF1/Cip1 and KILLER/DR5. This compound possesses tumor-suppressive properties.</p>Fórmula:C22H26N4OCor e Forma:SolidPeso molecular:362.47Microtubule inhibitor 2
<p>Microtubule inhibitor 2: potent, selective, oral, induces ferroptosis, strong antitumor effect.</p>Fórmula:C20H23NO7Cor e Forma:SolidPeso molecular:389.4DC-U4106
CAS:<p>DC-U4106: USP8 inhibitor, Kd 4.7μM, IC50 1.2μM, degrades Erα, low-toxicity tumor suppressor for breast cancer research.</p>Fórmula:C29H27N5O5Cor e Forma:SolidPeso molecular:525.56Anti-inflammatory agent 16
<p>Compound 14 is a peptidomimetic that significantly lowers TNFα, NO, CD40, and CD86, showcasing strong anti-inflammatory effects.</p>Fórmula:C21H23N5O3Cor e Forma:SolidPeso molecular:393.44eIF4A3-IN-6
CAS:<p>eIF4A3-IN-6 is a potent eIF4A inhibitor, potentially used for treating eIF4A-related diseases like cancer. (US20170145026A1)</p>Fórmula:C26H25N3O5Cor e Forma:SolidPeso molecular:459.49GGTI-2154 hydrochloride
CAS:<p>GGTI-2154 hydrochloride: selective GGTase I inhibitor, IC50 21 nM, used in cancer research.</p>Fórmula:C24H29ClN4O3Cor e Forma:SolidPeso molecular:456.97PI3K-IN-58
CAS:<p>PI3K-IN-58 (Compound 17f) is an inhibitor of PI3Kα with an IC50 value of 0.039 μM. It shows significant antiproliferative effects on PC-3, 22RV1, MDA-MB-231, and MDA-MB-453 cell lines with IC50 values of 3.48 μM, 1.06 μM, 2.21 μM, and 0.93 μM, respectively. PI3K-IN-58 induces apoptosis by downregulating the expression of anti-apoptotic proteins Bcl-XL and Bcl-2 while upregulating the expression of the pro-apoptotic protein BAX. This compound is applicable for research in cancer targeting through PI3K pathways.</p>Fórmula:C22H22N6O3SCor e Forma:SolidPeso molecular:450.51JAK-2/3-IN-3
<p>JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.</p>Fórmula:C13H10Cl2N4O2Cor e Forma:SolidPeso molecular:325.15PLK1-IN-15
CAS:<p>PLK1-IN-15 is a PLK1 inhibitor with an IC50 of 38.5 nM. It exhibits antiproliferative effects on HepG2, Huh7, H1299, and A549 cells, with IC50 values of 2.03, 2.08, 4.79, and 17.11 μM, respectively. Additionally, PLK1-IN-15 can induce cell cycle arrest in the G2/M phase and trigger apoptosis (Apoptosis), demonstrating anticancer activity.</p>Fórmula:C25H29N7O4SCor e Forma:SolidPeso molecular:523.61TrxR-IN-8
CAS:<p>TrxR-IN-8 (Compound 6f) is a selective inhibitor of TrxR with an IC50 of 10.2 μM. It induces apoptosis through oxidative stress by stimulating the production of reactive oxygen species, reducing intracellular thiols, and lowering the glutathione/glutathione disulfide ratio. TrxR-IN-8 exhibits significant cytotoxicity against non-small cell lung cancer (NSCLC) cells.</p>Fórmula:C16H16INO2Cor e Forma:SolidPeso molecular:381.21PD-L1/HDAC6-IN-1
CAS:<p>PD-L1/HDAC6-IN-1 (Compound HP29) is an inhibitor targeting both PD-L1 and HDAC6, effectively disrupting the PD-L1/PD-1 interaction and inhibiting HDAC6 activity, with IC50 values of 26.8 nM and 69 nM, respectively. This compound enhances the cytotoxicity of Jurkat T cells against HepG2 cells, exhibiting an IC50 of 3.4 μM. In rats, PD-L1/HDAC6-IN-1 demonstrates favorable pharmacokinetics, showing a drug exposure level of 871.62 ng·h/mL, and displays antitumor activity in a B16-F10 xenograft mouse model.</p>Fórmula:C27H33N3O3Cor e Forma:SolidPeso molecular:447.569BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Fórmula:C30H32N6O4Cor e Forma:SolidPeso molecular:540.61Apoptosis inducer 36
CAS:<p>Apoptosisinducer 36 (Compound 42) exhibits anti-leukemic activity by reducing leukemia stem cells (LSC) and inducing differentiation. It inhibits proliferation of AML cells by causing cell cycle arrest in the G1 phase, and induces PANoptosis, which includes apoptosis, pyroptosis, and necrosis.</p>Fórmula:C23H40O3SiCor e Forma:SolidPeso molecular:392.647Anticancer agent 45
<p>Anticancer agent 46, potent and selective, induces apoptosis, is cytotoxic to cancer cells, with low toxicity to human lymphocytes.</p>Fórmula:C22H14ClN3O6S2Cor e Forma:SolidPeso molecular:515.95EGFR-IN-47
<p>EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.</p>Fórmula:C29H35N7Cor e Forma:SolidPeso molecular:481.64GLS1 Inhibitor-6
<p>GLS1 Inhibitor-6: IC50=68nM, 220x more selective for GLS2, has anti-tumor and pro-apoptosis effects.</p>Fórmula:C37H52N6O3SCor e Forma:SolidPeso molecular:660.91CDK2-IN-9
<p>CDK2-IN-9: potent CDK2 inhibitor (IC50: 0.63 μM), anti-proliferative, arrests S/G2M cell cycle, induces apoptosis, promising for melanoma study.</p>Fórmula:C21H16ClN3O4SCor e Forma:SolidPeso molecular:441.89LSD1/ER-IN-1
<p>LSD1/ER-IN-1 inhibits ER & LSD1 (IC50: 1.55 μM), and fights MCF-7 breast cancer (IC50: 8.79 μM).</p>Fórmula:C23H18FNO6SCor e Forma:SolidPeso molecular:455.46
